South & Central America Osteoarthritis Therapy Market Forecast to 2030 - Regional Analysis - by Therapy Type (Transcutaneous Electrical Nerve Stimulation (TENS), Occupational Therapy, Physical Therapy, Platelet-Rich Plasma Therapy & Stromal Vascular Fract

South & Central America Osteoarthritis Therapy Market Forecast to 2030 - Regional Analysis - by Therapy Type (Transcutaneous Electrical Nerve Stimulation (TENS), Occupational Therapy, Physical Therapy, Platelet-Rich Plasma Therapy & Stromal Vascular Fraction, Prolotherapy, and Others), Disease Indication (Knee Osteoarthritis, Spine Osteoarthritis, Foot & Ankle Osteoarthritis, Shoulder Osteoarthritis, Hand Osteoarthritis, and Others), and End User (Hospitals & Clinics, Specialty Clinics, Ambulatory Surgical Centers, Homecare, and Others)

The South & Central America osteoarthritis therapy market was valued at US$ 345.44 million in 2022 and is expected to reach US$ 552.40 million by 2030; it is estimated to register a CAGR of 6.0% from 2022 to 2030.

More Effective Treatment Options Fuels South & Central America Osteoarthritis Therapy Market

Currently, there is no cure for OA. A group of clinical research scientists, through clinical trials, reveal that they are developing innovative treatment target options that can stop the progression of OA. For example, in November 2021, LG Chem company announced the initiation of a clinical trial for next-generation new drugs to treat arthritis. Additionally, in October 2021, Pacira BioSciences, Inc. announced the acquisition of Flexion Therapeutics to treat non-opioid pain management ZILRETTA. The drug approved in 2017 is the first and only approved treatment for OA knee pain utilizing extended-release microsphere technology.

In September 2023, Sorrento Therapeutics, Inc. announced positive Phase 2 top-line clinical trial results for the Resiniferatoxin (RTX) program. The Phase 2 trial is a multi-center, double-blind, placebo, and active-controlled study assessing the efficacy and safety of several dose groups of RTX to manage pain in patients with moderate-to-severe OAK. Also, Sorrento decided to include an active approved competitor drug, Zilretta, in the current clinical trial protocol.

South & Central America Osteoarthritis Therapy Market Overview

South & Central America countries comprises Brazil, Argentina, and Rest of South & Central America. The new product launches by the manufacturers to stay ahead in the competitive market is a significant factor responsible for market growth in South & Central America region. According to the Researchgate report, in Brazil, the prevalence of osteoarthritis is 33% among individuals over the age of 25, resulting in an estimated 40 million people suffering from the disorder. Additionally, the Korean Knee Society report reveals that osteoarthritis affects ~4% of the adult population in Brazil. The new product launches by the manufacturers to stay ahead in the competitive market is a significant factor responsible for market growth. For instance, in October 2018, Bioventus announced approval for DUROLANE from Agência Nacional de Vigilância Sanitária (ANVISA). The newly launched product is a single injection for OA treatment in Brazil. ANVISA approved DUROLANE for the symptomatic treatment of mild to moderate knee and hip OA. Therefore, innovative product launches in Brazil to treat osteoarthritis fuel the market growth.

South & Central America Osteoarthritis Therapy Market Revenue and Forecast to 2030 (US$ Million)

South & Central America Osteoarthritis Therapy Market Segmentation

The South & Central America osteoarthritis therapy market is categorized into therapy type, disease indications, end user, and country.

Based on therapy type, the South & Central America osteoarthritis therapy market is segmented into transcutaneous electrical nerve stimulation (TENS), occupational therapy, physical therapy, platelet-rich plasma (PRP) therapy & stromal vascular fraction, prolotherapy, and others. The physical therapy segment held the largest market share in 2022.

In terms of disease indications, the South & Central America osteoarthritis therapy market is segmented into knee osteoarthritis, spine osteoarthritis, foot and ankle osteoarthritis, shoulder osteoarthritis, hand osteoarthritis, and others. The knee osteoarthritis segment held the largest share of South & Central America in 2022.

Based on end user, the South & Central America osteoarthritis therapy market is categorized into hospitals and clinics, specialty clinics, ambulatory surgical center, homecare, and others. The homecare segment held the largest share of South & Central America in 2022.

By country, the South & Central America osteoarthritis therapy market is segmented into Brazil, Argentina, and the Rest of South & Central America. Brazil dominated the South & Central America share in 2022.

Zimmer Biomet Holdings Inc, DePuy Synthes Inc, Bioventus Inc, and Omron Healthcare Inc are some of the leading companies operating in the South & Central America osteoarthritis therapy market.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the South & Central America osteoarthritis therapy market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the South & Central America osteoarthritis therapy market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth South & Central America market trends and outlook coupled with the factors driving the South & Central America osteoarthritis therapy market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.